The stock of Keros Therapeutics Inc (KROS) has seen a -0.18% decrease in the past week, with a -32.36% drop in the past month, and a -81.29% decrease in the past quarter. The volatility ratio for the week is 5.10%, and the volatility levels for the past 30 days are at 6.31% for KROS. The simple moving average for the last 20 days is -13.31% for KROS stock, with a simple moving average of -76.15% for the last 200 days.
Is It Worth Investing in Keros Therapeutics Inc (NASDAQ: KROS) Right Now?
KROS has 36-month beta value of 1.38. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for KROS is 32.86M, and currently, short sellers hold a 12.23% ratio of that float. The average trading volume of KROS on January 30, 2025 was 1.44M shares.
KROS) stock’s latest price update
Keros Therapeutics Inc (NASDAQ: KROS)’s stock price has plunge by 0.53relation to previous closing price of 11.31. Nevertheless, the company has seen a -0.18% plunge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-29 that NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. (“Keros Therapeutics, Inc.”) (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, “announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
Analysts’ Opinion of KROS
Wedbush, on the other hand, stated in their research note that they expect to see KROS reach a price target of $15. The rating they have provided for KROS stocks is “Neutral” according to the report published on January 17th, 2025.
Oppenheimer gave a rating of “Outperform” to KROS, setting the target price at $63 in the report published on December 16th of the previous year.
KROS Trading at -64.41% from the 50-Day Moving Average
After a stumble in the market that brought KROS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.42% of loss for the given period.
Volatility was left at 6.31%, however, over the last 30 days, the volatility rate increased by 5.10%, as shares sank -30.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -81.97% lower at present.
During the last 5 trading sessions, KROS fell by -0.18%, which changed the moving average for the period of 200-days by -81.63% in comparison to the 20-day moving average, which settled at $13.12. In addition, Keros Therapeutics Inc saw -28.17% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KROS starting from GORDON CARL L, who sale 250,000 shares at the price of $44.01 back on Aug 13 ’24. After this action, GORDON CARL L now owns 119,522 shares of Keros Therapeutics Inc, valued at $11,002,500 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Keros Therapeutics Inc, sale 250,000 shares at $44.01 during a trade that took place back on Aug 13 ’24, which means that ORBIMED ADVISORS LLC is holding 119,522 shares at $11,002,500 based on the most recent closing price.
Stock Fundamentals for KROS
Current profitability levels for the company are sitting at:
- -313.42 for the present operating margin
- -0.27 for the gross margin
The net margin for Keros Therapeutics Inc stands at -278.91. The total capital return value is set at -0.37. Equity return is now at value -43.82, with -40.10 for asset returns.
Based on Keros Therapeutics Inc (KROS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.28.
Currently, EBITDA for the company is -152.18 million with net debt to EBITDA at 2.6. When we switch over and look at the enterprise to sales, we see a ratio of -78.08. The receivables turnover for the company is 0.34for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.03.
Conclusion
To put it simply, Keros Therapeutics Inc (KROS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
